These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30689703)

  • 1. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Delaloge S; Cella D; Ye Y; Buyse M; Chan A; Barrios CH; Holmes FA; Mansi J; Iwata H; Ejlertsen B; Moy B; Chia SKL; Gnant M; Smichkoska S; Ciceniene A; Martinez N; Filipović S; Ben-Baruch NE; Joy AA; Langkjer ST; Senecal F; de Boer RH; Moran S; Yao B; Bryce R; Auerbach A; Fallowfield L; Martin M
    Ann Oncol; 2019 Apr; 30(4):567-574. PubMed ID: 30689703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
    Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
    Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
    Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
    Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
    [No Abstract]   [Full Text] [Related]  

  • 6. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
    Lüftner D; Tesch H; Schmidt M; Hartkopf AD; Streicher S; Resch A; Genovese L; Rosé C; Valenti R; Harbeck N
    Eur J Cancer; 2021 Jun; 150():268-277. PubMed ID: 33971386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
    Holmes FA; Moy B; Delaloge S; Chia SKL; Ejlertsen B; Mansi J; Iwata H; Gnant M; Buyse M; Barrios CH; Silovski T; Šeparović R; Bashford A; Zotano AG; Denduluri N; Patt D; Gokmen E; Gore I; Smith JW; Loibl S; Masuda N; Tomašević Z; Petráková K; DiPrimeo D; Wong A; Martin M; Chan A;
    Eur J Cancer; 2023 May; 184():48-59. PubMed ID: 36898233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
    Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M;
    Clin Breast Cancer; 2021 Feb; 21(1):80-91.e7. PubMed ID: 33183970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer.
    Singh H; Walker AJ; Amiri-Kordestani L; Cheng J; Tang S; Balcazar P; Barnett-Ringgold K; Palmby TR; Cao X; Zheng N; Liu Q; Yu J; Pierce WF; Daniels SR; Sridhara R; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Aug; 24(15):3486-3491. PubMed ID: 29523624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
    Dhillon S
    Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer.
    Blanter J; Baldwin E; Patel R; Sheng T; Tiersten A
    Breast Cancer Res Treat; 2024 Nov; 208(2):461-466. PubMed ID: 39153126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
    Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
    Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
    O'Sullivan CC; Ballman KV; McCall L; Kommalapati A; Zemla T; Weiss A; Mitchell M; Blinder V; Tung NM; Irvin WJ; Lee M; Goetz MP; Symmans WF; Borges VF; Krop I; Carey LA; Partridge AH
    Future Oncol; 2021 Dec; 17(34):4665-4676. PubMed ID: 34636255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER
    Sudhan DR; Schwarz LJ; Guerrero-Zotano A; Formisano L; Nixon MJ; Croessmann S; González Ericsson PI; Sanders M; Balko JM; Avogadri-Connors F; Cutler RE; Lalani AS; Bryce R; Auerbach A; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(2):771-783. PubMed ID: 30274983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
    Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
    Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
    Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
    JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neratinib for the treatment of HER2-positive early stage breast cancer.
    Echavarria I; López-Tarruella S; Márquez-Rodas I; Jerez Y; Martin M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):669-679. PubMed ID: 28649882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
    Boyle FM; Smith IE; O'Shaughnessy J; Ejlertsen B; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Amonkar M; Huang Y; Rappold E; Williams LS; Wang-Silvanto J; Kaneko T; Finkelstein DM; Goss PE;
    Eur J Cancer; 2015 Apr; 51(6):685-96. PubMed ID: 25752740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.